January 6, 2014 Top Pros’ Top Picks Our top stock selection for 2014 has received three Breakthrough Therapy Designations (BTD) by the FDA, and subsequent approval, in November, for Imbruvica, a very safe pill that has shown unprecedented efficacy to treat mantle cell lymphoma (MCL), suggests John McCamant, editor of The Medical Technology Stock Letter.[…]
Tag: MDCO
WSJ – Why Following the Winners Is for Losers (1-3-14)
January 3, 2014 Why Following the Winners Is for Losers by Mark Hulbert “Past performance is no guarantee of future results.” This phrase, ubiquitous in the small print of financial products, often falls on deaf ears, according to Adam Reed, a finance professor at the University of North Carolina at Chapel Hill. “Investors have a[…]
MDCO – To Bleed Or Not To Bleed, They Answer The Question
The Medicines Company (MDCO â $30.92) â To Bleed Or Not Bleed, They Answer The Question New Recommendation â MDCO â The Medicines Company (MDCO) is a new recommendation at MTSL with a BUY UNDER 35 with TARGET PRICE of 50. Focused on acute care medicine in the hospital setting, MDCO markets three proprietary drugs, has[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
The Medicines Company (1-9-14)
The Medicines Company (MDCO) – The transformation that began last year is expected to gain further momentum in 2014. The Company is delivering on its plan to become the leading acute care provider of medicines in the hospital setting – in acute cardiovascular care, surgical and perioperative medicine, and hospital-based infectious disease. At least three[…]
Moneyshow – Profits in Pain Prevention (12-20-13)
December 23, 2013 Profits in Pain Prevention The Medical Technology Stock Letter had one of the best performing stocks in this past year’s Top Picks special; here, Jay Silverman updates his view on this biotech winner and highlights some potential new leaders for the coming year. Steve Halpern: We’re here today with biotech expert Jay Silverman[…]
Moneyshow – Top Pros’ Top Picks (1-10-14)
January 10, 2014 Top Pros’ Top Picks Stocks of biotechnology companies that reach major inflection points tend to outperform for several years. And our top speculative idea is a company that made a major leap forward in 2013, suggests Jay Silverman, editor of The Medical Technology Stock Letter. Novavax (NVAX) is executing its clinical plan[…]
Biotechs Update (11-7-13)
MTSL Special Update – Biotech Stocks – November 7, 2013 Biotech Stocks – Sell Off Accelerates As Investors Rush to Lock In 2013 Profits and “Risk Off” Includes Top Tier, Too. The current collapse was triggered by: a) Technical factors – A number of stocks failed to reach new highs despite bounces after the shock[…]